Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Mounjaro and Rivaroxaban Interaction: What Patients and Clinicians Need to Know

By
Published Updated Last reviewed
6 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Interaction type / Theoretical absorption effect from delayed gastric emptying; no named label interaction [1]
  • Rivaroxaban in Mounjaro label / Not named; the oral-medicine caution applies as a class [1]
  • Mounjaro label wording / May affect absorption of oral medicines; monitor narrow-therapeutic-index drugs, example warfarin [1]
  • Rivaroxaban class / Oral direct factor Xa inhibitor
  • Food effect / 80% to 100% bioavailability for the 15 mg and 20 mg tablets when taken with food [2]
  • Peak rivaroxaban level / 2 to 4 hours after the tablet [2]
  • Half-life / 5 to 9 hours in healthy young adults, 11 to 13 hours in elderly [2]
  • Routine level checks / Not part of DOAC therapy; anti-Xa testing used in specific situations [3]

What does the Mounjaro label say about other medicines?

The drug interactions section of the Mounjaro label is short. It has one paragraph on insulin and sulfonylureas and one on oral medicines in general [1]. The oral paragraph says tirzepatide delays gastric emptying and therefore has the potential to affect absorption of drugs taken by mouth. It advises caution and says to monitor patients on oral drugs that depend on threshold concentrations for efficacy and those with a narrow therapeutic index, using warfarin as its example [1].

Rivaroxaban is not named in that section. The general caution covers oral drugs as a class, but the label does not describe a specific tirzepatide-rivaroxaban interaction.

How large is the absorption effect?

The label gives absorption numbers for acetaminophen. After a first 5 mg dose of tirzepatide, acetaminophen peak concentration fell 55% and peak time arrived about 1 hour later. By week 6, on 15 mg once weekly, there was no meaningful effect on acetaminophen peak concentration or peak time, and total exposure was unchanged [1]. The label says the gastric-emptying delay is largest after the first dose and diminishes over time [1]. These findings do not establish how Mounjaro affects rivaroxaban absorption.

Does tirzepatide change how rivaroxaban is metabolized?

Tirzepatide is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the fatty diacid and amide hydrolysis, rather than by CYP enzymes [1]. It has low in vitro potential to inhibit or induce CYP enzymes [1].

Rivaroxaban and food

Rivaroxaban has 80% to 100% bioavailability for the 10 mg tablet regardless of food and for the 15 mg and 20 mg tablets when taken with food [2]. The Xarelto label says the 15 mg and 20 mg tablets must be taken with food, while 2.5 mg and 10 mg tablets can be taken with or without food. Peak plasma concentrations arrive 2 to 4 hours after the tablet. The half-life is 5 to 9 hours in healthy young adults and 11 to 13 hours in elderly patients [2].

Bleeding, GI side effects and kidney function

The Mounjaro label describes gastrointestinal reactions, sometimes severe, and acute kidney injury from volume depletion, mostly in people with nausea, vomiting or diarrhea. It advises monitoring kidney function in patients with GI reactions that could lead to volume depletion [1]. Tirzepatide needs no dose adjustment for kidney or liver impairment.

Rivaroxaban dosing depends on the indication and kidney function, and dose reduction is indicated in atrial fibrillation with renal impairment [4]. The Mounjaro label does not address rivaroxaban dosing.

Frequently asked questions

Can Mounjaro and rivaroxaban be taken together?
The Mounjaro label does not list a specific interaction with rivaroxaban. It treats oral medicines as a class, warns that delayed gastric emptying may change absorption, and names warfarin, not rivaroxaban, as its narrow-therapeutic-index example [1].
Does tirzepatide slow rivaroxaban absorption?
It is not known. The label says tirzepatide may change absorption of oral medicines, but its absorption measurements were made with acetaminophen: after a first 5 mg dose, peak acetaminophen fell 55% and arrived about 1 hour later, while at week 6 on 15 mg there was no meaningful effect on peak or total exposure [1].
Do I need extra blood tests on both drugs?
Direct oral anticoagulants are not managed with routine laboratory monitoring [3]. When a quantitative rivaroxaban measurement is useful, an anti-Xa assay is the preferred test; the appropriate sampling time depends on why the level is being checked [3]. The Mounjaro label advises monitoring kidney function in people with GI reactions that could cause volume depletion [1].
Should rivaroxaban be taken with food?
The Xarelto label says the 15 mg and 20 mg tablets must be taken with food; the 2.5 mg and 10 mg tablets can be taken with or without food. Bioavailability is 80% to 100% for the 10 mg tablet regardless of food and for the 15 mg and 20 mg tablets with food [2].
Does Mounjaro raise bleeding risk on rivaroxaban?
The effect of the combination on bleeding has not been measured. The Mounjaro label describes gastrointestinal reactions and volume-depletion-related kidney injury [1]. Rivaroxaban's own bleeding risk is documented: in ROCKET AF, major plus non-major clinically relevant bleeding was 14.9% versus 14.5% per year against warfarin [5]. In COMPASS, major bleeding occurred in 3.1% of participants receiving rivaroxaban 2.5 mg twice daily plus aspirin and 1.9% of those receiving aspirin alone [6].

References

  1. U.S. National Library of Medicine, DailyMed. Mounjaro injection and KwikPen (tirzepatide) prescribing information. Mounjaro injection and KwikPen (tirzepatide) label
  2. Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1-16. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban
  3. Douxfils J, Ageno W, Samama CM, Lessire S, Ten Cate H, Verhamme P, et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018;16(2):209-219. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians
  4. Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol. 2017;69(23):2779-2790. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction
  5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
  6. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319-1330. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
Evidence overview for Mounjaro and Rivaroxaban Interaction: What Patients and Clinicians Need to Know